Search research articles
Contact Us
Filters
Showing results (341-350 of 386) with videos related to
Page
of 39
Sort By:
Journal for Immunotherapy of Cancer
|
November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Toni K Choueiri, Harriet Kluger, Saby George, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
The Pharmacogenomics Journal
|
March 4, 2024
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
Jai N Patel, Chen Jiang, Kouros Owzar, et al.
International Journal of Cancer
|
September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial
Amir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Nature Communications
|
January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
Journal of Patient-Reported Outcomes
|
June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
Tomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2014
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer
Amir Goldkorn, Benjamin Ely, David I Quinn, et al.
Clinical Genitourinary Cancer
|
June 6, 2017
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421
Guru Sonpavde, Gregory R Pond, Melissa Plets, et al.
The Oncologist
|
April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)
Adel Mandl, Ruizhe Chen, Satya Das, et al.
Page
of 39
Search research articles
Search
Showing results (341-350 of 386) with videos related to
Sort By:
Page
of 39
Journal for Immunotherapy of Cancer
|
November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Toni K Choueiri, Harriet Kluger, Saby George, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
The Pharmacogenomics Journal
|
March 4, 2024
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
Jai N Patel, Chen Jiang, Kouros Owzar, et al.
International Journal of Cancer
|
September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial
Amir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Nature Communications
|
January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
Journal of Patient-Reported Outcomes
|
June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
Tomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2014
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer
Amir Goldkorn, Benjamin Ely, David I Quinn, et al.
Clinical Genitourinary Cancer
|
June 6, 2017
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421
Guru Sonpavde, Gregory R Pond, Melissa Plets, et al.
The Oncologist
|
April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)
Adel Mandl, Ruizhe Chen, Satya Das, et al.
Page
of 39